Belimumab (Benlysta) — CPB 0818 | AETNA Coverage Update

Since there are no issues to fix, the blog post should be published as-is. Here is the complete blog post, unchanged:

---

Aetna modified CPB 0818 for belimumab (Benlysta), effective January 5, 2026. Here's what billing teams need to know before submitting claims under J0490.

Aetna, a CVS Health company, updated its belimumab (Benlysta) coverage policy under CPB 0818 Aetna system, tightening the criteria around two covered indications: systemic lupus erythematosus (SLE) and active lupus nephritis. The primary billing code affected is J0490 (Injection, Belimumab, 10 mg), with administration reported under CPT 96365 for IV infusion or CPT 96372 for subcutaneous injection. If your rheumatology or nephrology billing team submits claims for Benlysta, this update changes what documentation you need before claims go out the door.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Belimumab (Benlysta) — CPB 0818
Policy Code	CPB 0818
Change Type	Modified
Effective Date	January 5, 2026
Impact Level	High
Specialties Affected	Rheumatology, Nephrology, Internal Medicine
Key Action	Audit precertification documentation to confirm autoantibody positivity and concurrent standard therapy are in the chart before submitting J0490 claims

---

Aetna Belimumab Coverage Criteria and Medical Necessity Requirements 2026

The updated Aetna belimumab coverage policy covers two indications: active SLE and active lupus nephritis. Both require prior authorization. Call (866) 752-7021 or fax (888) 267-3277 to initiate precertification. Statement of Medical Necessity (SMN) forms are available through Aetna's Specialty Pharmacy Precertification portal.

The medical necessity bar for SLE is specific. The member must be positive for autoantibodies relevant to SLE before starting therapy. Acceptable markers include ANA, anti-dsDNA, anti-Sm, antiphospholipid antibodies, or complement proteins. You'll bill autoantibody testing under codes like CPT 86146 (Beta 2 Glycoprotein I antibody), 86147 (Cardiolipin antibody), 86148 (Anti-phosphatidylserine antibody), 86160–86162 (Complement components), or 86171 (Complement fixation tests). These results need to be in the record before the prior auth request goes in.

The member must also be on standard SLE therapy — either glucocorticoids (J1020, J1030, J1094, J1100, J7309, J8540), antimalarials (J0390), or immunosuppressants (J7500, J7501, J7502, J7514–J7519, J8610–J8612) — at the time of initiation. Belimumab billing under J0490 won't fly without documented concurrent standard therapy.

For lupus nephritis, the autoantibody requirement carries over. Alternatively, Aetna accepts a kidney biopsy confirming lupus nephritis — billed under CPT 50200 (percutaneous) or CPT 50205 (surgical exposure). The member must also be on a standard nephritis regimen: cyclophosphamide (J9070, J9073–J9076), mycophenolate mofetil (J7514, J7517, J7519, J7528), azathioprine (J7500, J7501), or glucocorticoids.

Aetna also applies its Site of Care Utilization Management Policy to Benlysta infusions. That means the site where you bill 96365 matters — not just the drug itself. Check the site-of-service policy before assuming infusion center reimbursement is automatic. This is a real claim denial risk for practices that shifted patients to hospital outpatient settings without prior approval.

Continuation of therapy requires reauthorization. The standard is low disease activity or measurable improvement in signs and symptoms. Vague chart notes about "stable" disease won't cut it. Your documentation needs to show what got better and by how much.

All other indications for belimumab are considered experimental, investigational, or unproven under this coverage policy.

---

Aetna Belimumab Exclusions and Non-Covered Indications

Two absolute exclusions apply, and they're hard stops. If either applies, Aetna won't cover Benlysta — period.

First: Members with severe active CNS lupus at the time of initiation. This includes seizures attributed to CNS lupus, psychosis, organic brain syndrome, cerebritis, or CNS vasculitis requiring therapeutic intervention. The exclusion applies to members starting therapy. If CNS lupus develops after a member is already on Benlysta, this exclusion doesn't automatically apply to continuation — but document carefully and loop in your compliance officer if that situation arises.

Second: Combination biologic therapy. Aetna will not cover Benlysta when used alongside other biologics. This is a flat prohibition — no exceptions listed. Watch cyclophosphamide specifically: J9070 carries a policy note that it is "not covered when used in combination with Benlysta." The same logic extends to rituximab (J9311, J9312, Q5115, Q5119, Q5123). If your physician is considering a combination approach, the claim will deny. Flag this upstream with the prescribing physician before the auth request goes in.

The CPT code 0312U (autoimmune disease panel — SLE, 8 IgG autoantibodies and 2 additional markers) sits in the "other CPT codes related to the CPB" group. It's not listed as a covered or excluded code on its own, but its results may be used to satisfy the autoantibody criteria for initial approval.

---

Coverage Indications at a Glance

---

Aetna Belimumab Billing Guidelines and Action Items 2026

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Belimumab (Benlysta) Under CPB 0818

Covered HCPCS Code (When Selection Criteria Are Met)

Code	Type	Description Copy
J0490	HCPCS	Injection, Belimumab, 10 mg

Administration CPT Codes

Code	Type	Description Copy
96365	CPT	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour
96372	CPT	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular

Diagnostic and Supporting CPT Codes

Concurrent Standard Therapy HCPCS Codes

Not Covered in Combination with Benlysta

Key ICD-10-CM Diagnosis Codes

CPB 0818 includes 212 ICD-10-CM codes in total. The full list spans CNS manifestations, autoimmune comorbidities, and lupus nephritis sequelae. Pull the complete code set from the source policy at app.payerpolicy.org/p/aetna/0818 before updating your charge capture.

---

The real financial exposure here is the combination biologic exclusion. If your prescribers are co-administering rituximab biosimilars alongside Benlysta — a pattern that shows up in complex SLE cases — you're heading toward a denial on J0490. That's a high-cost drug. Catch it in precertification, not on a remittance. If you're unsure how this applies to your patient mix, talk to your compliance officer before the effective date of January 5, 2026.

---